Skip to main content
Figure 2 | Radiation Oncology

Figure 2

From: Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Figure 2

Western blot analysis of the effects of sunitinib, with or without irradiation, on three of its trans-membrane receptor targets. Both total and phosphorylated forms of PDGFR-β, VEGFR2, and C-KIT were detected by western blot analysis. Both DU145 (A) and PC3 (B) cells were treated with sunitinib (40, 100, 250 nM for 24 hours) and harvested for western blot analysis 2 h after irradiation. β-Actin was used as a loading control.

Back to article page